1. RxSight faces a class action lawsuit for securities fraud violations. 2. Investors are encouraged to join before the September 22, 2025 deadline. 3. The lawsuit claims RxSight made false statements affecting share performance. 4. Allegations include overstating product demand and financial guidance failures. 5. Investors suffered damages when market truths were revealed.
The allegations of fraud and false statements can severely harm investor trust, leading to a decline. Historically, companies facing similar lawsuits have seen stock price drops, e.g., Valeant Pharmaceuticals.
The content directly pertains to investor rights and company integrity, crucial for RXST's market image.
The immediate concern arises from market reactions to the lawsuit. Previous similar events triggered rapid stock declines, often within weeks of announcement.
LOS ANGELES, Aug. 18, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against RxSight, Inc. ("RxSight" or "the Company") (NASDAQ: RXST) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities between November 7, 2024 and July 8, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before September 22, 2025.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. RxSight experienced "adoption challenges" causing declining sales and utilization rates. The Company overstated customer demand for its products. The Company was unlikely to achieve its financial guidance for fiscal year 2025. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about RxSight, investors suffered damages
Join the case to recover your losses.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/rxst-investors-have-opportunity-to-lead-rxsight-inc-securities-fraud-lawsuit-with-the-schall-law-firm-302531926.html
SOURCE The Schall Law Firm